At the news
? NEUTRALIMPACT 3/10 SC 13G filed Nov 10, 2026 at 09:35 ET
State Street Corporation filed a Schedule 13G disclosing a 4.6% passive stake in Vir Biotechnology as of September 30, 2026, down from 12.4% reported by BlackRock in the prior 13G/A. This is a routine passive filing by a large asset manager with no activist intent.
- State Street Corp disclosed beneficial ownership of 7,822,781 shares of Vir Biotechnology common stock as of September 30, 2026
- The stake represents 4.6% of shares outstanding
- Filing certifies passive intent under Rule 13d-1(b) with no control intent
- State Street is a large asset manager (custodian bank) filing as a parent holding company
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access